|
1
|
Choy E, Ganeshalingam K, Semb AG,
Szekanecz Z and Nurmohamed M: Cardiovascular risk in rheumatoid
arthritis: Recent advances in the understanding of the pivotal role
of inflammation, risk predictors and the impact of treatment.
Rheumatology (Oxford). 53:2143–2154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
del R, incón I, Polak JF, O'Leary DH,
Battafarano DF, Erikson JM, Restrepo JF, Molina E and Escalante A:
Systemic inflammation and cardiovascular risk factors predict rapid
progression of atherosclerosis in rheumatoid arthritis. Ann Rheum
Dis. 74:1118–1123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Breukelen-van der Stoep DF, Klop B,
van Zeben D, Hazes JM and Castro Cabezas M: Cardiovascular risk in
rheumatoid arthritis: How to lower the risk? Atherosclerosis.
231:163–172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soubrier M, Barber Chamoux N, Tatar Z,
Couderc M, Dubost JJ and Mathieu S: Cardiovascular risk in
rheumatoid arthritis. Joint Bone Spine. 81:298–302. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aviña-Zubieta JA, Choi HK, Sadatsafavi M,
Etminan M, Esdaile JM and Lacaille D: Risk of cardiovascular
mortality in patients with rheumatoid arthritis: A meta-analysis of
observational studies. Arthritis Rheum. 59:1690–1697. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smolen JS, van der Heijde D, Machold KP,
Aletaha D and Landewé R: Proposal for a new nomenclature of
disease-modifying antirheumatic drugs. Ann Rheum Dis. 73:3–5. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Visser K and van der Heijde D: Optimal
dosage and route of administration of methotrexate in rheumatoid
arthritis: A systematic review of the literature. Ann Rheum Dis.
68:1094–1099. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smolen JS, Landewé R, Bijlsma J, Burmester
G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van
Vollenhoven R, et al: EULAR recommendations for the management of
rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis.
76:960–977. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu Q and Lin CS: Plasma levels of D-dimer
in a 5-year-old girl with systemic juvenile idiopathic arthritis: A
case report and literature review. Exp Ther Med. 11:1027–1030.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Z, Chen Z, Yang S, Wang Y, Yu L,
Zhang B, Rao Z, Gao J and Tu S: (1)H NMR-based metabolomic analysis
for identifying serum biomarkers to evaluate methotrexate treatment
in patients with early rheumatoid arthritis. Exp Ther Med.
4:165–171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Negrei C, Bojinca V, Balanescu A, Bojinca
M, Baconi D, Spandidos DA, Tsatsakis AM and Stan M: Management of
rheumatoid arthritis: Impact and risks of various therapeutic
approaches. Exp Ther Med. 11:1177–1183. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hochberg M, Silman AJ, Smolen J, Weinblatt
M and Weisman M: Methotrexate. Rheumatology. 1. 6th. Elsevier; pp.
442–450. 2015
|
|
13
|
Ganguly P and Alam SF: Role of
homocysteine in the development of cardiovascular disease. Nutr J.
14:62015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Negrei C, Căruntu C, Ginghină O, Burcea
Dragomiroiu G, Toderescu C and Boda D: Qualitative and quantitative
determination of methotrexate polyglutamates in erythrocytes by
high performance liquid chromatography. Rev Chim. 66:607–610.
2015.
|
|
15
|
Chan ES and Cronstein BN: Methotrexate-how
does it really work? Nat Rev Rheumatol. 6:175–178. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Ede AE, Laan RF, Blom HJ, Boers GH,
Haagsma CJ, Thomas CM, De Boo TM and van de Putte LB: Homocysteine
and folate status in methotrexate-treated patients with rheumatoid
arthritis. Rheumatology (Oxford). 41:658–665. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng HY, Man CF, Xu J and Fan Y: Elevated
homocysteine levels and risk of cardiovascular and all-cause
mortality: A meta-analysis of prospective studies. J Zhejiang Univ
Sci B. 16:78–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Bai YY, Luo LM, Xiao WK, Wu HM
and Ye P: Association between serum homocysteine and arterial
stiffness in elderly: A community-based study. J Geriatr Cardiol.
11:32–38. 2014.PubMed/NCBI
|
|
19
|
Basu A, Jenkins AJ, Stoner JA, Thorpe SR,
Klein RL, Lopes-Virella MF, Garvey WT and Lyons TJ: DCCT/ EDIC
Research Group: Plasma total homocysteine and carotid intima-media
thickness in type 1 diabetes: A prospective study. Atherosclerosis.
236:188–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pang X, Liu J, Zhao J, Mao J, Zhang X,
Feng L, Han C, Li M, Wang S and Wu D: Homocysteine induces the
expression of C-reactive protein via NMDAr-ROS-MAPK-NF-κB signal
pathway in rat vascular smooth muscle cells. Atherosclerosis.
236:73–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shenoy V, Mehendale V, Prabhu K, Shetty R
and Rao P: Correlation of serum homocysteine levels with the
severity of coronary artery disease. Indian J Clin Biochem.
29:339–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lim U and Cassano PA: Homocysteine and
blood pressure in the Third National Health and Nutrition
Examination Survey, 1988–1994. Am J Epidemiol. 156:1105–1113. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peeters AC, van der Molen EF, Blom HJ and
den Heijer M: The effect of homocysteine reduction by B-vitamin
supplementation on markers of endothelial dysfunction. Thromb
Haemost. 92:1086–1091. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mangge H, Becker K, Fuchs D and Gostner
JM: Antioxidants, inflammation and cardiovascular disease. World J
Cardiol. 6:462–477. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cronstein B: How does methotrexate
suppress inflammation? Clin Exp Rheumatol. 28 (Suppl 61):S21–S23.
2010.PubMed/NCBI
|
|
26
|
Reiss AB, Rahman MM, Chan ES, Montesinos
MC, Awadallah NW and Cronstein BN: Adenosine A2A
receptor occupancy stimulates expression of proteins involved in
reverse cholesterol transport and inhibits foam cell formation in
macrophages. J Leukoc Biol. 76:727–734. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reiss AB, Carsons SE, Anwar K, Rao S,
Edelman SD, Zhang H, Fernandez P, Cronstein BN and Chan ES:
Atheroprotective effects of methotrexate on reverse cholesterol
transport proteins and foam cell transformation in human THP-1
monocyte/macrophages. Arthritis Rheum. 58:3675–3683. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dinarello CA: Immunological and
inflammatory functions of the interleukin-1 family. Annu Rev
Immunol. 27:519–550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zimmerman MC, Clemens DL, Duryee MJ,
Sarmiento C, Chiou A, Hunter CD, Tian J, Klassen LW, O'Dell JR,
Thiele GM, et al: Direct antioxidant properties of methotrexate:
Inhibition of malondialdehyde-acetaldehyde-protein adduct formation
and superoxide scavenging. Redox Biol. 13:588–593. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Charles-Schoeman C, Yin Lee Y, Shahbazian
A, Wang X, Elashoff D, Curtis JR, Navarro-Millán I, Yang S, Chen L,
Cofield SS, et al: Improvement of high-density lipoprotein function
in patients with early rheumatoid arthritis treated with
methotrexate monotherapy or combination therapies in a randomized
controlled trial. Arthritis Rheumatol. 69:46–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hjeltnes G, Hollan I, Førre O, Wiik A,
Lyberg T, Mikkelsen K and Agewall S: Serum levels of lipoprotein(a)
and E-selectin are reduced in rheumatoid arthritis patients treated
with methotrexate or methotrexate in combination with
TNF-α-inhibitor. Clin Exp Rheumatol. 31:415–421. 2013.PubMed/NCBI
|
|
32
|
Deyab G, Hokstad I, Whist JE, Smastuen MC,
Agewall S, Lyberg T, Ronda N, Mikkelsen K, Hjeltnes G and Hollan I:
Methotrexate and anti-tumor necrosis factor treatment improves
endothelial function in patients with inflammatory arthritis.
Arthritis Res Ther. 19:2322017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kisiel B, Kruszewski R, Juszkiewicz A,
Raczkiewicz A, Bachta A, Tłustochowicz M, Staniszewska-Varga J,
Kłos K, Duda K, Bogusławska-Walecka R, et al: Methotrexate,
cyclosporine A, and biologics protect against atherosclerosis in
rheumatoid arthritis. J Immunol Res. 2015:7596102015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim HJ, Kim MJ, Lee CK and Hong YH:
Effects of methotrexate on carotid intima-media thickness in
patients with rheumatoid arthritis. J Korean Med Sci. 30:1589–1596.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Woodman RJ, Baghdadi LR, Shanahan ME and
Mangoni AA: The temporal relationship between arterial stiffening
and blood pressure is modified by methotrexate treatment in
patients with rheumatoid arthritis. Front Physiol. 8:5932017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Micha R, Imamura F, Wyler von Ballmoos M,
Solomon DH, Hernán MA, Ridker PM and Mozaffarian D: Systematic
review and meta-analysis of methotrexate use and risk of
cardiovascular disease. Am J Cardiol. 108:1362–1370. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Westlake SL, Colebatch AN, Baird J, Kiely
P, Quinn M, Choy E, Ostor AJ and Edwards CJ: The effect of
methotrexate on cardiovascular disease in patients with rheumatoid
arthritis: A systematic literature review. Rheumatology (Oxford).
49:295–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Solomon DH, Goodson NJ, Katz JN, Weinblatt
ME, Avorn J, Setoguchi S, Canning C and Schneeweiss S: Patterns of
cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis.
65:1608–1612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roman MJ and Salmon JE: Cardiovascular
manifestations of rheumatologic diseases. Circulation.
116:2346–2355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De Vecchis R, Baldi C and Palmisani L:
Protective effects of methotrexate against ischemic cardiovascular
disorders in patients treated for rheumatoid arthritis or
psoriasis: Novel therapeutic insights coming from a meta-analysis
of the literature data. Anatol J Cardiol. 16:2–9. 2016.PubMed/NCBI
|
|
41
|
Roubille C, Richer V, Starnino T, McCourt
C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, et al:
The effects of tumour necrosis factor inhibitors, methotrexate,
non-steroidal anti-inflammatory drugs and corticosteroids on
cardiovascular events in rheumatoid arthritis, psoriasis and
psoriatic arthritis: A systematic review and meta-analysis. Ann
Rheum Dis. 74:480–489. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wasko MC, Dasgupta A, Hubert H, Fries JF
and Ward MM: Propensity-adjusted association of methotrexate with
overall survival in rheumatoid arthritis. Arthritis Rheum.
65:334–342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Choi HK, Hernán MA, Seeger JD, Robins JM
and Wolfe F: Methotrexate and mortality in patients with rheumatoid
arthritis: A prospective study. Lancet. 359:1173–1177. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tabit CE, Holbrook M, Shenouda SM,
Dohadwala MM, Widlansky ME, Frame AA, Kim BH, Duess MA, Kluge MA,
Levit A, et al: Effect of sulfasalazine on inflammation and
endothelial function in patients with established coronary artery
disease. Vasc Med. 17:101–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ridker PM, Everett BM, Thuren T, MacFadyen
JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker
SD, et al: CANTOS Trial Group: Antiinflammatory therapy with
canakinumab for atherosclerotic disease. N Engl J Med.
377:1119–1131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Everett BM, Pradhan AD, Solomon DH,
Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P,
Hasan AA, et al: Rationale and design of the Cardiovascular
Inflammation Reduction Trial: A test of the inflammatory hypothesis
of atherothrombosis. Am Heart J. 166:199–207.e15. 2013. View Article : Google Scholar : PubMed/NCBI
|
